969 related articles for article (PubMed ID: 18438829)
1. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
2. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
[TBL] [Abstract][Full Text] [Related]
3. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
[TBL] [Abstract][Full Text] [Related]
4. Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis.
Mattey DL; Dawes PT; Clarke S; Fisher J; Brownfield A; Thomson W; Hajeer AH; Ollier WE
Arthritis Rheum; 2002 Aug; 47(4):403-7. PubMed ID: 12209487
[TBL] [Abstract][Full Text] [Related]
5. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
[TBL] [Abstract][Full Text] [Related]
6. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis.
Kapitány A; Szabó Z; Lakos G; Aleksza M; Végvári A; Soós L; Karányi Z; Sipka S; Szegedi G; Szekanecz Z
Isr Med Assoc J; 2008 Jan; 10(1):32-6. PubMed ID: 18300568
[TBL] [Abstract][Full Text] [Related]
7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
8. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
[TBL] [Abstract][Full Text] [Related]
9. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations.
van der Woude D; Lie BA; Lundström E; Balsa A; Feitsma AL; Houwing-Duistermaat JJ; Verduijn W; Nordang GB; Alfredsson L; Klareskog L; Pascual-Salcedo D; Gonzalez-Gay MA; Lopez-Nevot MA; Valero F; Roep BO; Huizinga TW; Kvien TK; Martín J; Padyukov L; de Vries RR; Toes RE
Arthritis Rheum; 2010 May; 62(5):1236-45. PubMed ID: 20131291
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
11. Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.
Lundström E; Källberg H; Smolnikova M; Ding B; Rönnelid J; Alfredsson L; Klareskog L; Padyukov L
Arthritis Rheum; 2009 Apr; 60(4):924-30. PubMed ID: 19333936
[TBL] [Abstract][Full Text] [Related]
12. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
13. A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis.
Gourraud PA; Dieudé P; Boyer JF; Nogueira L; Cambon-Thomsen A; Mazières B; Cornélis F; Serre G; Cantagrel A; Constantin A
Arthritis Res Ther; 2007; 9(2):R27. PubMed ID: 17328818
[TBL] [Abstract][Full Text] [Related]
14. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
Allaart CF; Breedveld FC; Dijkmans BA
J Rheumatol Suppl; 2007 Nov; 80():25-33. PubMed ID: 17985420
[TBL] [Abstract][Full Text] [Related]
15. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.
Huizinga TW; Amos CI; van der Helm-van Mil AH; Chen W; van Gaalen FA; Jawaheer D; Schreuder GM; Wener M; Breedveld FC; Ahmad N; Lum RF; de Vries RR; Gregersen PK; Toes RE; Criswell LA
Arthritis Rheum; 2005 Nov; 52(11):3433-8. PubMed ID: 16255021
[TBL] [Abstract][Full Text] [Related]
16. Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity.
Vander Cruyssen B; Miltenburg AM; Van den Bosch F; Houbiers JG; Wittoek R; Boots AM; De Keyser F
J Rheumatol; 2007 Oct; 34(10):1992-6. PubMed ID: 17924607
[TBL] [Abstract][Full Text] [Related]
17. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.
van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122
[TBL] [Abstract][Full Text] [Related]
18. Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset.
González-Gay MA; Hajeer AH; García-Porrúa C; Dababneh A; Thomson W; Ollier WE; Mattey DL
J Rheumatol; 2002 Feb; 29(2):271-5. PubMed ID: 11842822
[TBL] [Abstract][Full Text] [Related]
19. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
[TBL] [Abstract][Full Text] [Related]
20. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
